Intranasal administration of human fibroblast interferon in mice, rats, rabbits and dogs.
In previous studies on the nasal administration of human fibroblast interferon (HuIFN-beta), only rabbits have been used. Therefore, this route was investigated in mice, rats, rabbits and dogs. HuIFN-beta could be delivered across the nasal mucosa in mice, rats, rabbits and dogs, when it was mixed with sodium glycocholate as an absorption promoter. However, the pattern of the plasma HuIFN-beta concentration-time curve was different from that in rabbits. Rabbits gave the highest value of the maximum plasma HuIFN-beta concentration (Cmax), but plasma HuIFN-beta declined rapidly thereafter, upon nasal administration of the powder dosage form (8.45 x 10(2) IU/g). In rats and dogs, Cmax was lower than in rabbits, but plasma HuIFN-beta declined slowly after nasal administration of the powder or liquid dosage form (4-6 x 10(2) IU/g). These differences might be attributed to differences of absorption rate constant.
Igawa
T
T
Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
Maitani
Y
Y
Machida
Y
Y
Nagai
T
T
D000281:Administration, Intranasal; D000818:Animals; D004285:Dogs; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051379:Mice; D008815:Mice, Inbred Strains; D011817:Rabbits; D051381:Rats; D013045:Species Specificity
D007370:Interferon Type I